Treatment with Mirvetuximab-Soravtansin—first clinical experience in advanced ovarian cancer in a comprehensive cancer center
Treatment with MIRV has been shown to be promising in advanced ovarian cancer. In a small heterogeneous group of heavily pretreated patients, general recommendations for therapy with MIRV are limited. Close collaboration with ophthalmology and patient education is essential to mitigate ocular events.
Authors
- Jakob Neubauer (ORCID: https://orcid.org/0000-0001-9388-0219)
- Sarah Huwer
- I. Schwörer
- Lisa Jung
- Ingolf Juhasz-Böss
- B. Rautenberg
Institutions
- University Medical Center Freiburg (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-19
- DOI
- https://doi.org/10.3389/fonc.2026.1732304
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00